Lucid Diagnostics Inc (LUCD)

Apr 11, 2025, 10:53 AM EDT - 12 days ago

Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

Apr 11, 2025, 9:23 AM EDT - 12 days ago

Lucid Diagnostics Announces Closing of Public Offering of Common Stock

PAVM

Apr 9, 2025, 7:24 PM EDT - 14 days ago

Lucid Diagnostics Announces Pricing of Public Offering of Common Stock

PAVM

Apr 9, 2025, 4:01 PM EDT - 14 days ago

Lucid Diagnostics Announces Proposed Public Offering of Common Stock

PAVM

Apr 3, 2025, 9:00 AM EDT - 20 days ago

Lucid Diagnostics to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

PAVM

Mar 27, 2025, 8:01 AM EDT - 27 days ago

Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology

PAVM

Mar 24, 2025, 12:17 PM EDT - 4 weeks ago

Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 8:01 AM EDT - 4 weeks ago

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

PAVM

Mar 20, 2025, 8:31 AM EDT - 4 weeks ago

Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening

PAVM

Mar 18, 2025, 8:31 AM EDT - 5 weeks ago

Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PAVM

Mar 13, 2025, 7:36 AM EDT - 5 weeks ago

Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test

PAVM

Mar 10, 2025, 9:01 AM EDT - 6 weeks ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025

PAVM

Mar 5, 2025, 4:45 PM EST - 7 weeks ago

Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

PAVM

Mar 4, 2025, 8:25 AM EST - 7 weeks ago

Lucid Diagnostics Announces $15.3 Million Registered Direct Offering

PAVM

Feb 27, 2025, 8:31 AM EST - 7 weeks ago

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

PAVM

Feb 25, 2025, 8:31 AM EST - 2 months ago

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PAVM

Feb 20, 2025, 8:31 AM EST - 2 months ago

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

PAVM

Feb 18, 2025, 8:30 AM EST - 2 months ago

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

PAVM

Feb 6, 2025, 8:57 AM EST - 2 months ago

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

PAVM

Jan 13, 2025, 7:56 AM EST - 3 months ago

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

PAVM

Dec 23, 2024, 8:01 AM EST - 4 months ago

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

PAVM

Dec 19, 2024, 8:01 AM EST - 4 months ago

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

PAVM

Dec 11, 2024, 8:01 AM EST - 4 months ago

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

PAVM

Dec 3, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

PAVM

Nov 20, 2024, 7:56 AM EST - 5 months ago

Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test

PAVM

Nov 18, 2024, 8:15 AM EST - 5 months ago

Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

PAVM

Nov 13, 2024, 2:44 PM EST - 5 months ago

Lucid Diagnostics Inc. (LUCD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results

PAVM

Nov 7, 2024, 8:01 AM EST - 5 months ago

Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication

PAVM

Nov 5, 2024, 8:01 AM EST - 6 months ago

Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

PAVM

Oct 30, 2024, 8:31 AM EDT - 6 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024

PAVM

Oct 15, 2024, 7:51 AM EDT - 6 months ago

Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test

PAVM

Oct 9, 2024, 1:46 PM EDT - 7 months ago

October's 4 Best Penny Stocks: High-Risk, High-Reward Picks

ALUR GEVO KULR

Oct 9, 2024, 8:01 AM EDT - 7 months ago

Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit

PAVM

Oct 8, 2024, 7:49 AM EDT - 7 months ago

Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024

PAVM

Sep 24, 2024, 8:01 AM EDT - 7 months ago

American Foregut Society's 2024 Annual Meeting to Highlight Lucid Diagnostics' EsoGuard Esophageal Precancer Test

PAVM

Sep 16, 2024, 4:30 PM EDT - 7 months ago

PAVmed Announces Efforts to Regain Compliance with Nasdaq Listing Requirements

PAVM

Sep 10, 2024, 7:56 AM EDT - 8 months ago

Lucid Diagnostics to Host Symposium on Non-Endoscopic Esophageal Precancer Screening at the 20th International Society for Diseases of the Esophagus (ISDE) World Congress

PAVM

Sep 3, 2024, 7:51 AM EDT - 8 months ago

Lucid Diagnostics Signs Memorandum of Understanding with Front Line Mobile Health

PAVM

Aug 20, 2024, 8:16 AM EDT - 8 months ago

Lucid Diagnostics Announces Publication of Analytical Validation Study of EsoGuard® for Early Detection of Esophageal Precancer and Cancer

PAVM

Aug 13, 2024, 8:16 AM EDT - 9 months ago

The American Foregut Society Formally Requests Medical Policy Coverage of EsoGuard® to Enhance Early Detection of Esophageal Cancer

PAVM

Aug 13, 2024, 8:01 AM EDT - 9 months ago

PAVmed Provides Business Update and Second Quarter 2024 Financial Results

PAVM

Aug 12, 2024, 1:32 PM EDT - 9 months ago

Lucid Diagnostics Inc. (LUCD) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:07 AM EDT - 9 months ago

Lucid Diagnostics Provides Business Update and Second Quarter 2024 Financial Results

PAVM

Aug 8, 2024, 8:31 AM EDT - 9 months ago

Lucid Diagnostics Holds First Major Directly-Contracted EsoGuard® #CheckYourFoodTube Precancer Testing Event

PAVM

Aug 6, 2024, 8:15 AM EDT - 9 months ago

Lucid Diagnostics Announces Positive Data from ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing

PAVM

Aug 5, 2024, 8:15 AM EDT - 9 months ago

Lucid Diagnostics to Participate in Upcoming Investor Conferences

PAVM

Jul 29, 2024, 8:15 AM EDT - 9 months ago

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 12, 2024

PAVM

Jul 11, 2024, 8:31 AM EDT - 10 months ago

Lucid Diagnostics Launches New Corporate Website

PAVM

Jul 2, 2024, 7:55 AM EDT - 10 months ago

Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

PAVM